A humanized monoclonal antibody targeting cell surface glycoprotein CS1, expressed in tumor cells of more than 95% of patients with multiple myeloma, but minimally expressed in normal cells.

Trade name Empliciti.

Administered intravenously.

A Humanized immunoglobulin G1 immunostimulatory monoconal antibody targeted against signaling lymphocytic activation molecule F7 (SLAMF7, also called CS1)a cell surface glycoprotein expressed on myeloma and natural killer cells but not on normal tissues that enables selective killing of myeloma cells with minimal effects on healthy tissues.

Its activity is delivered primarily by NK cell mediately antibody dependent cell mediated cytotoxicity and antibody dependent cellular phagocytosis.

Elotuzumab for the treatment of patients with multiple myeloma who have received one or more prior therapies.

The drug is a monoclonal antibody targeted against Signaling Lymphocyte Activation Molecule (SLAMF7, also called CS1), a glycoprotein expressed on myeloma and natural killer cells, but not detectable in normal cells.

SLAM Family member 7 , is also known as CD 319, CRACC is a glycoprotein expressed on the surface of plasma cells and natural killer cells.

SLAMF7 belongs to the family of signaling lymphocyte activating molecule related receptor proteins, promoting cell growth in survival normal normal and malignant plasma cells.

SLAMF7 induce his cell death in multiple myeloma cells and acts by directly activating NK cells and recruiting the SLAM-associated adaptive protein EAT-2.

Has a dual mechanism of action, by directly activating natural killer (NK) cells as well as tags myeloma cells for destruction through antibody-dependent cellular cytotoxicity (ADCC).

Findings from a randomized Phase II, open-label study that evaluated two dose levels of the drug in combination with lenalidomide and low-dose dexamethasone in previously-treated patients with multiple myeloma.

Phase III trials for the drug are now ongoing as first-line treatment (ELOQUENT-1), as well as in relapsed or refractory disease (ELOQUENT-2).

Approved for combination treatment with lenalidomide and dexamethasone for treatment of patients with multiple myeloma who have failed 1-3 prior regimens.

Approved for the treatment of patients with a relapsed/refractory multiple myeloma with Pomalidomide and dexamethasone-ELOQUENT-3trial.

Can cause infusion reactions with fever, chills, hypertension, bradycardia and hypotension.

5% of patients require interruption of the administration due to infusion reactions.

Patients should be premedicated with dexamethasone, acetaminophen, H1 and H2 blockers.

Available as 300 and 400 mg vials.

Dose 10mg/kg intravenously once a week for the first 2 cycles and once every 2 weeks thereafter.

Cycles of treatment are 28 days.

Prior to drug infusion dexamethasone oral dexamethasone and IV dexamethasone are administered.

Leave a Reply Cancel reply